Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

and should not forget about bone protective agents for mCRPC!

Read the full article here

Related Articles